Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 41Active not recruiting 5Withdrawn 3Terminated 2Unknown 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Pancreatic Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × veliparib × Clear all
NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
16 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT01282333 2013-07-02

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
44 enrolled
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡